Epithalon Spray 10 mg

One-Peptides EPITHALON 10 mg — AEDG bioregulator tetrapeptide nasal spray for laboratory research

This product is a laboratory reagent intended solely for scientific research (Research Use Only, RUO). It is not a medicinal product, a dietary supplement or a cosmetic. It is not intended for use in humans or animals, nor for the diagnosis, treatment, mitigation or prevention of any condition. The material may be purchased and handled only by adults (21+) conducting research work under laboratory conditions. All numerical data, sequences and descriptions of mechanisms relate to the characterisation of the substance and to the scientific literature, not to usage recommendations.

The Russian school of peptide bioregulators, developed from the 1970s and 1980s by Vladimir Khavinson’s team at the St. Petersburg Institute of Bioregulation and Gerontology, rests on the premise that short peptides may act as signalling molecules regulating tissue activity. One of the compounds most frequently described in this tradition is Epithalon — a synthetic analogue of epithalamin, a peptide extract from the pineal gland (the gland responsible, among other things, for the rhythm of melatonin secretion). Rather than working with a crude tissue extract, researchers synthesised a short, chemically defined tetrapeptide of reproducible composition, which makes quality control and experimental reproducibility easier.

The nasal spray format is a choice dictated by the research context, not a usage recommendation. Peptide bioregulators are sometimes analysed in the literature across various routes of administration, and intranasal administration is sometimes considered as a route that bypasses the gastrointestinal tract. The solution is supplied in a pre-dissolved form — ready to work with in an atomiser, with no need to reconstitute a powder — which simplifies the standardisation of concentration between samples. Epithalon (Epitalon, Epithalone) is a synthetic bioregulator tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG) and a molecular weight of approximately 390 Da, developed as a defined analogue of epithalamin. In the scientific literature — chiefly in preclinical models and Russian works — its effect on telomerase activity in vitro and on pineal gland regulation has been analysed.

What Epithalon is — sequence and class

Epithalon belongs to the family of so-called short regulatory peptides (bioregulators), which the Khavinson literature describes as molecules that may potentially influence gene expression and tissue function. Its structure is exceptionally simple: just four amino acids joined in a chain. The AEDG sequence (alanine–glutamic acid–aspartic acid–glycine) is fixed and constitutes the chemical “identity” of the compound — it is this sequence, confirmed by mass spectrometry, that distinguishes authentic research material from a substance of different composition.

Unlike epithalamin, which is an extract mixture of variable composition, Epithalon is a single, defined molecule. As a result, experiments can be planned around a known molar mass and a known sequence, and results are easier to compare between laboratories.

Chemical characterisation

Mechanism of action in research

The mechanisms attributed to Epithalon derive primarily from laboratory studies — cellular (in vitro) and animal — and should be treated as experimental observations rather than as a confirmed effect in humans. The strength of this evidence is limited by the provenance of the literature and by the small number of independent replications.

The most frequently discussed theme is telomerase activity in vitro. Telomerase is an enzyme that replenishes telomeres — the ends of chromosomes that shorten with successive cell divisions. In some culture studies it was observed that the presence of the AEDG tetrapeptide was associated with an increase in telomerase activity in selected cell lines. This is an observation at the cellular level under controlled culture conditions — no conclusions about the human organism should be drawn from it.

A second theme is the regulation of the pineal gland and the melatonin rhythm. Because Epithalon derives from a pineal gland extract, its relationship with the circadian profile of melatonin secretion and with chronobiology has been analysed in animal models. A third area is the effect on gene expression — the Russian literature described a hypothesis that short peptides may act at the level of gene activity regulation. All these directions remain at the stage of basic research and require independent confirmation.

Nasal spray format — research context

Intranasal administration is sometimes considered in the literature as a route that bypasses the barrier of the gastrointestinal tract and first-pass hepatic metabolism. In the case of peptide bioregulators studied across various routes of administration, the atomiser format is sometimes used in experimental protocols on account of the simplicity of dosing volumes and the reproducibility of application within a model.

It should, however, be stated honestly: for Epithalon itself there is a lack of hard clinical data regarding the intranasal route in humans. The use of this form in research work therefore rests on the general context of research into peptides, rather than on a verified, published clinical precedent for this specific molecule. The pre-dissolved solution in an atomiser simplifies standardisation: a constant concentration and a known drop volume make it easier to reproduce conditions between laboratory samples.

State of research — the nature and limitations of the evidence

This is the most important section for a sound assessment of this material. Most of the available literature on Epithalon comes from a single centre and a single school of science — the St. Petersburg Institute of Bioregulation and Gerontology and collaborating researchers (including Khavinson, Anisimov). A substantial proportion of the works was published in the Russian-language scientific circuit, poorly indexed in international databases and often without DOI identifiers, which hampers verification and independent access.

This gives rise to specific limitations that need to be borne in mind:

• Preclinical models predominate — cell cultures and animal studies; there is a lack of large, independent, randomised controlled trials with a control group.
• Limited independent replication — many important observations have not been replicated by teams outside the original research school, which weakens their credibility.
• Difficult source verification — the dispersion of the literature and gaps in indexing hamper a full assessment of the methodology.

In practice this means that Epithalon is an interesting object of basic research, yet it does not possess a body of evidence comparable to that of registered active substances. Any claim about its effect should be framed with appropriate caution.

Applications in scientific research

In a laboratory context, the AEDG tetrapeptide is sometimes used as a reference compound in several areas of basic research. The points below describe directions present in the literature — these are not usage applications or protocols for humans:

• Research into telomerase activity — as a tool for observing changes in enzyme activity in selected cell lines in vitro and in models of cellular ageing.
• Chronobiology and melatonin — the peptide’s relationship with the circadian rhythm and with the profile of melatonin secretion by the pineal gland has been analysed in animal models.
• Models of cellular ageing — Epithalon is sometimes used as a research compound in experiments on the biology of ageing, including on gene expression in cultures.

Each of these directions remains at the level of preclinical research and requires independent verification.

One Peptides quality specification

The credibility of research results depends on the quality and reproducibility of the material. For Epithalon nasal spray 10 mg, One Peptides applies the following control standard:

• HPLC purity ≥ 98% — high-performance liquid chromatography confirming the peptide content.
• MS identity confirmation — mass spectrometry verifying the molecular weight and the AEDG sequence.
• COA for each batch (per batch) — a certificate of analysis attached to the specific production batch.
• Cold chain — controlled temperature conditions in storage and transport, important for the stability of the peptide in solution.
• Batch traceability — the ability to assign the material to a specific batch and its documentation.

Safety and limitations

This section describes observations from the research literature, not a safety profile for a product intended for use in humans. In the available preclinical models, the AEDG tetrapeptide was sometimes described as well tolerated under experimental conditions. This should, however, be read in the context of the earlier reservations: it concerns observations from cultures and animal models, not a clinical assessment.

The most important interpretive limitations:

• A lack of long-term data in humans — there is no body of clinical research that would allow the safety of chronic exposure in humans to be assessed.
• Caution regarding claims of slowing ageing — the popular narratives attributing to Epithalon a life-extending effect or the “rebuilding” of telomeres in humans go beyond what has been demonstrated in sound research. The observations concerning telomerase come from the cellular level and do not automatically translate to the organism.
• Laboratory use only — the material requires handling by qualified personnel, with adherence to good practice in working with reagents.

Regulatory status and WADA

Epithalon is supplied as a Research Use Only laboratory reagent. It is not authorised for sale as a medicinal product or a dietary supplement — it holds no registration with any medicines agency (e.g. EMA, FDA) as a product intended for use in humans. It must not be administered to humans or animals outside strictly controlled, legally permitted research conditions.

With regard to sport: on the World Anti-Doping Agency (WADA) list of prohibited substances and methods, Epithalon does not appear by name as a banned substance. This should not, however, be interpreted as an encouragement to any use — the product remains a research reagent, not an agent for use.

Frequently asked questions

What is Epithalon and what does AEDG mean?
Epithalon (Epitalon, Epithalone) is a synthetic bioregulator tetrapeptide with a weight of approximately 390 Da. The abbreviation AEDG corresponds to its amino acid sequence Ala-Glu-Asp-Gly. It is a chemically defined analogue of epithalamin — a peptide extract from the pineal gland — developed in the Russian school of peptide bioregulators.

What does research say about telomerase?
In some culture studies (in vitro), an association was observed between the AEDG tetrapeptide and an increase in telomerase activity in selected cell lines. This should be read with caution: these are observations at the cellular level under controlled conditions, coming chiefly from the literature of a single research school and with limited independent replication. They do not constitute proof of an effect in humans.

Is it an anti-ageing agent?
No. Epithalon in this format is a Research Use Only research reagent, not an anti-ageing agent, a medicine or a supplement. Narratives about life extension or rejuvenation through the “rebuilding” of telomeres in humans go beyond what has been demonstrated in sound research.

Why the nasal spray format?
Intranasal administration is sometimes considered in the literature as a route that bypasses the gastrointestinal tract. In laboratory work, an atomiser makes reproducible dosing of volumes easier. For Epithalon itself, however, there is a lack of hard intranasal clinical data in humans — this is a research context, not a recommendation.

How should the material be stored to maintain stability?
The peptide solution requires cold chain conditions. Detailed recommendations on storage temperature are given in the COA attached to the relevant batch. Stability in solution is one of the reasons for applying a controlled temperature in storage and transport.

Bibliography

1. Khavinson VKh et al. (2004). Peptide promotes overcoming of the division limit in human somatic cell
2. Anisimov VN et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence
3. Khavinson VKh. Peptides and Ageing (review; no verified DOI)
4. Korkushko OV, Khavinson VKh et al. (2004). Effect of peptide preparation Epithalamin on circadian rhythm of melatonin

Nature of the evidence: in the works above — chiefly animal models and cellular studies originating from the Russian literature (St. Petersburg Institute of Bioregulation and Gerontology) — the themes described were analysed. This literature is under-indexed in the Crossref database, which is why the DOI identifiers require independent verification, and the conclusions should be treated as preliminary and not covered by large independent clinical trials.

Product intended solely for research purposes (Research Use Only). It is not a medicinal product, a dietary supplement or an agent intended for consumption or for administration to humans or animals. It does not serve for the diagnosis, treatment or prevention of any condition. Sold only to adults (21+) for laboratory applications. The purchaser acknowledges the research nature of the material and handles it in accordance with good practice in working with reagents.